Prevalence and predictors of hepatic steatosis in adults with newly diagnosed chronic liver disease due to hepatitis C

Medicine

Volumn 88, Issue 5, 2009, Pages 302-306

  Hayman, Amanda V ^a   Sofair, Andre N ^b   Manos, M Michele ^c   Thomas, Ann ^d   Terrault, Norah ^e   Ness, Grace Van ^d   Stabach, Nicole ^b   Robert, Marie ^b   Rumore, Gregory ^f   Corless, Christopher ^a   Bell, Beth ^g   Bialek, Stephanie ^g   Zaman, Atif ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DIVISION OF RESEARCH   (United States)

^d OREGON PUBLIC HEALTH DIVISION   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f KAISER PERMANENTE MEDICAL CENTER   (United States)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ESTROGEN; IMMUNOMODULATING AGENT;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CHRONIC LIVER DISEASE; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; INTERVIEW; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OBESITY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; UNITED STATES;

ADULT; AGED; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; FIBROSIS; HEPATITIS C, CHRONIC; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; ODDS RATIO; PREVALENCE; RISK FACTORS; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 70349659663     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/MD.0b013e3181b954f4     Document Type: Article

References (27)

1. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33:1358-1364.
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WK, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999-2002. Ann Intern Med. 2006;144:705-714.
3. Bell BP, Manos MM, Zaman A, Terrault N, Thomas A, Navarro VJ, Dhotre KB, Murphy RC, Van Ness GR, Stabach N, Robert ME, Bower WA, Bialek SR, Sofair AN. The epidemiology of newly diagnosed chronic liver disease in the United States: results from population-based surveillance. Am J Gastroenterol. 2008;103: 2727-2736.
4. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology. 2003;38:639-644.
5. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147-152.
6. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94: 2467-2474.
7. Centers for Disease Control and Prevention. Obesity. Available at http://www.cdc.gov/nccdphp/dnpa/obesity/. Accessed 19 April 2006.
8. Cholet F, Nousbaum JB, Richecoeur M, Oger E, Cauvin JM, Lagarde N, Robaszkiewicz M, Gouerou H. Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients.Gastroenterol Clin Biol. 2004;28:272-278.
9. Dulworth S, Patel S, Pyenson BS. The hepatitis C epidemic: looking at the tip of the iceberg. Washington, DC: Milliman & Robertson;2000.
10. Elgar FJ, Roberts C, Tudor-Smith C, Moore L. Validity of self-reported height and weight and predictors of bias in adolescents. J Adolesc Health. 2005;37:371-375.
11. Finkelstein EA, Fiebelkorn IC, Wang G. National medical spending attributable to overweight and obesity: how much, and who's paying? Health Aff (Millwood). 2003;14 May. [Jan-Jun; Suppl Web Exclusives:W3-219-226.]
12. Harrison SA, Di Bisceglie AM. Advances in the understanding and treatment of nonalcoholic fatty liver disease. Drugs. 2003;63:2379-2394.
13. Hickman IJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, Ash S, Jonsson JR, Powell EE. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut. 2002;51: 89-94.
14. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999;29: 1215-1219.
15. Hui JM, Kench J, Farrell GC, Lin R, Samarasinghe D, Liddle C, Byth K, George J. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol. 2002;17: 873-881.
16. Hwang SJ, Luo JC, Chu CW, Lai CR, Lu CL, Tsay SH, Wu JC, Chang FY, Lee SD. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol. 2001;16: 190-195.
17. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology. 2002;36:1266-1272.
18. Ludwig J. The nomenclature of chronic active hepatitis: an obituary. Gastroenterology. 1993;105:274-278.
19. McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol. 2002;34:255-262.
20. Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci. 2005;330:326-335.
21. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, Heaton S, Conrad A, Pockros PJ, McHutchison JG. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.J Hepatol. 2004;40:484-449.
22. Poynard T, Ratziu V, McHutchison J. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003;38:75-85. (Pubitemid 36775798)
23. Romero-Gomez M, Castellano-Megias VM, Grande L, Irles JA, Cruz M, Nogales MC, Alcon JC, Robles A. Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. Am J Gastroenterol. 2003;98:1135-1141. (Pubitemid 36733778)
24. Skinner HA, Sheu WJ. Reliability of alcohol use indices. The Lifetime Drinking History and the MAST. J Stud Alcohol. 1982; 43:1157-1170.
25. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90:1562-1569.
26. Younossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A, Bringman D, Martin LM, Assmann J, Gramlich T, Mullen KD, O'Shea R, Carey WD, Ferguson R. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol. 2004;38:705-709.
27. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med. 2004;140:370-381.